admin | April 29, 2021
February 12, 2015
The order in which someone with an MPN acquires a genetic mutation may effect their prognosis, says an article published today in the New England Journal of Medicine. Researchers from the U.K. were able to determine the order in which people with myeloproliferative neoplasms acquired the TET2 and JAK2 mutations, which influenced response to therapy, the biology of stem and progenitor cells and clonal evolution.